Cross-Sector entity
Perrigo is most often covered alongside Acushnet, which appears in 1 of these 2 stories. The clearest coverage concentration is earnings: 1 of 2 stories, with the rest divided among 1 other category. We currently track 2 Cross-Sector stories that mention Perrigo, all published on February 27, 2026.
2 verified stories tracked
Last mentioned: Feb 27, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Perrigo is most often covered alongside Acushnet, which appears in 1 of these 2 stories. The clearest coverage concentration is earnings: 1 of 2 stories, with the rest divided among 1 other category. We currently track 2 Cross-Sector stories that mention Perrigo, all published on February 27, 2026. Each carries 19 original sources on average.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Perrigo. Shared-story counts are live from our verified record — not editorial picks.
The final quarter of 2025 revealed a sector-wide shift toward operational discipline and high-margin product expansion among leading biotech and pharma entities. Key players like Indivior and Pacira reported significant volume growth in flagship therapies while successfully navigating patent challenges and portfolio optimizations.
The Q4 2025 earnings cycle highlights a bifurcated retail landscape where premium brands like Acushnet and Wolverine are successfully navigating macro headwinds through innovation. Meanwhile, retail technology providers like NCR Voyix and Payoneer are accelerating their shift toward high-margin recurring revenue and B2B services.
